During Monday’s Morning trade, Shares of Lululemon Athletica inc. (NASDAQ:LULU), gained 4.00% to $51.22.
lululemon athletica inc. (LULU), declared that its financial results for the third quarter fiscal year 2015 will be released Wednesday, December 9, 2015. The company will host a conference call at 9:00 a.m. Eastern time to discuss the financial results.
lululemon athletica inc., together with its auxiliaries, designs, manufactures, and distributes athletic apparel and accessories for women, men, and female youth. It operates through two segments, Corporate-Owned Stores and Direct To Consumer.
Shares of Hibbett Sports, Inc. (NASDAQ:HIBB), inclined 2.10% to $33.98, during its current trading session.
Hibbett Sports, Inc. (NASDAQ/GS: HIBB):
- EPS improvements 17.9% to $0.79 per diluted share (counting favorable impact of $0.05 per diluted share resulting from legal settlement)
- Comparable store sales improvements 0.6%
- Updates Fiscal 2016 Guidance
- Board authorizes new stock repurchase program of $300 million
- Hibbett Sports, declared results for the third quarter ended October 31, 2015.
Third Quarter Results
Net sales for the 13-week period ended October 31, 2015, raised 4.6% to $228.3 million contrast with $218.3 million for the 13-week period ended November 1, 2014. Comparable store sales for the third quarter raised 0.6%.
Gross profit was 36.1% of net sales for the 13-week period ended October 31, 2015, contrast with 36.3% of net sales for the 13-week period ended November 1, 2014. Product margin was flat, although store occupancy and logistics costs raised as a percentage of net sales due to the deleveraging effect of lower comparable store sales.
Store operating, selling and administrative expenses were 21.1% of net sales for the 13-week period ended October 31, 2015, contrast with 22.1% of net sales for the 13-week period ended November 1, 2014. These expenses were lower as a percentage of net sales mainly due to a favorable legal settlement.
Net income for the 13-week period ended October 31, 2015, was $18.7 million contrast with $16.9 million for the 13-week period ended November 1, 2014. Earnings per diluted share totaled $0.79 for the 13-week period ended October 31, 2015, contrast with $0.67 for the 13-week period ended November 1, 2014. The impact of the favorable legal settlement contributed $0.05 per diluted share to the 13-week period ended October 31, 2015.
Hibbett Sports, Inc., together with its auxiliaries, operates sporting goods retail stores in small and mid-sized markets primarily in the South, Southwest, Mid-Atlantic, and the Midwest regions of the United States. Its stores offer a range of merchandise, counting athletic footwear, team sports equipment, athletic and fashion apparel, and related accessories.
Finally, Shares of Merck & Co., Inc. (NYSE:MRK), lost -0.15%, and is now trading at $54.01.
Eli Lilly and Company and Merck (MRK), known as MSD outside the United States and Canada, declared the extension of an existing partnership to evaluate the safety and efficacy of the combination of Lillys ALIMTA® (pemetrexed for injection) and Mercks KEYTRUDA® (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). The study will be sponsored by Merck and will be open to patients with NSCLC in the first-line setting, regardless of PD-L1 status. Financial details of the partnershipwere not revealed.
The expansion of this oncology clinical trial partnership comes following the release of encouraging data from a Phase I study, presented earlier this year at the 16th World Congress on Lung Cancer, which evaluated pemetrexed, carboplatin and pembrolizumab in first-line nonsquamous NSCLC.
Pemetrexed is a leading therapeutic option used in combination with platinum-based therapies in this setting, making it an ideal candidate for combination studies with immunotherapy treatments. Pembrolizumab is a humanized monoclonal antibody that works by increasing the ability of the bodys immune system to assist detect and fight tumor cells. Pembrolizumab blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes, which may affect both tumor cells and healthy cells – and is presently approved as a single-agent therapy for certain types of NSCLC.
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; antidepressants; ophthalmic and cholesterol modification products; non-sedating antihistamine; and vaginal contraceptive implants.